REAL WORLD TESTING RESULTS REPORT - 2024

Prepared By: Haroon Sher

GENERAL INFORMATION

Report ID Number	**[20231130mdf]**
Developer Name	**MediFusion, LLC**
Product Name(s)	**MediFusion**
Version Number(s)	**V2.0**
Certified Health IT Product List (CHPL) ID(s)	**15.05.05. 3102.MEDF.01.00.1.220228**
Developer Real World Testing Plan Page URL	**https://medifusion.com/real-world-testing/**
Developer Real World Testing Results Page URL	**https://medifusion.com/real-world-testing-results/**

[OPTIONAL] CHANGES TO ORIGINAL PLAN

Summary of Change [Summarize each element that changed between the plan and actual execution of Real World Testing]	**Reason** [Describe the reason this change occurred]	**Impact** [Describe what impact this change had on the execution of your Real-World Testing activities]
1. Adjustment of Testing Methodology for Low-Use Criteria: Criteria 170.315(f)(1), (f)(2), (f)(3), (b)(7), (b)(8) were tested using interactive, semi-controlled methods.	As noted in the original plan, these certified capabilities exhibited minimal to no active use in live customer production environments during the 2024 testing window. To demonstrate functional compliance as permitted by ONC guidance, testing was conducted in a secure, production-mirrored environment using simulated data and transactions that replicate real-world workflows.	This change ensured all certification criteria could be validated for functionality and standards compliance. It did not impact the validity of the test results for these specific interoperability features.
2. Refinement of Outcome Metrics for Clarity: The specific numerical outcomes reported for several measures (e.g., RWT #2, #5, #9) have been updated to directly align with the metric definitions in the 2024 RWT Plan (e.g., reporting percentages where percentages were defined).	Initial data compilation presented aggregate counts. To ensure strict adherence to the plan's metric definitions and provide unambiguous results, data was re-analyzed to calculate the precise percentages or counts as stipulated per the defined measurement period (e.g., 90-day).	This refinement enhances the accuracy, clarity, and direct comparability of the results against the planned metrics and expected outcomes.
3. Addition of RWT Measure #13 for API Resource Query: A new measure focusing on the FHIR API transaction success rate was added to the results reporting.	The 2024 RWT Plan's Measure #9 (API Resource Query Support) encompasses criteria 170.315(g)(7), (g)(9), and (g)(10). To provide a clear, singular success metric for the core FHIR API functionality (g10), this supplemental result was derived from the same data set collected for Measure #9.	This addition provides a focused, quantitative outcome for the widely-used single-patient FHIR API, offering a clear indicator of real-world performance without requiring additional client testing.

[OPTIONAL] WITHDRAWN PRODUCTS

We have not withdrawn any products within the past year that we previously included in the Real-World Testing plan.

SUMMARY OF TESTING METHODS AND KEY FINDINGS

Aligned with the ONC's proposal that "Real World Testing confirms that implemented Certified Health IT keeps functioning as intended by carrying out and monitoring observations of data sharing and interoperability," the original test strategy we devised was centered on counting and recording the number of real-world examples in which a certified capability was applied effectively. When there is no proof because a certified capacity is not used very often or at all, or when evidence cannot be captured,

We tested and showed the necessary certified capacity in a semi-controlled setting as close to a "real world" implementation as possible, in order to ensure its effective application for various purposes.

We used a three-pronged strategy in accordance with the test plan to show effective real-world implementations.

We used a three-pronged strategy in accordance with the test plan to show effective real-world implementations.

- Adoption Rate
- Summative Testing
- Interactive Testing

Adoption rate was utilized to help discover variations in care settings and to ascertain whether or not certified capacity is being used in the real world. High rates of usage and implementation are indicators of a certified capability's practical worth and usefulness, but they do not prove it on their own. Low rates of implementation and utilization may be explained, among other things, by the number of patients, the region, or the provider's preference. Note that the purpose of this exercise is to identify the users and care settings rather than to determine the specific reasons why a certain certified capability may have a high or low adoption rate. Summative evaluations were employed to gauge which approved actions were completed within a specified time frame, with a minimum of ninety days, and extended periods when feasible. To show how frequently actions were taken within the allotted time range and, if possible, whether or not those actions were successful, these data are usually generated by analyzing audit logs from inside the certified health IT module. A successful business should have high success rates as a sign. application of a specific certified competency in a practical situation. When a certified capability's adoption rate is zero, interactive testing is utilized to show compliance with requirements and to show continuous adherence to updated code sets and standards (SVAP). Live testing of interactive tests was done instead of looking at usage data from the past. The intention is to show how the certified Health IT module is applied consistently in a practice or healthcare environment. This methodology facilitated the efficacious testing and acquisition of outcomes for every criterion. The reader will find supporting information for each certified criterion for MediFusion in the Metrics and Outcomes section, which is detailed below. This information takes the form of a Summative result or interactive test results.

STANDARDS UPDATES (INCLUDING STANDARDS VERSION ADVANCEMENT PROCESS (SVAP) AND UNITED STATES CORE DATA FOR INTEROPERABILITY (USCDI))

Both required and voluntary standards updates must be addressed in the Real-World Testing plan. Real World Testing plans must include all certified health IT updated to newer versions of standards prior to August 31 of the year in which the updates were made.

Indicate as to whether optional standards, via SVAP and/or USCDI, are leveraged as part of the certification of your health IT product(s).

_____Yes, I have products certified with voluntary SVAP or USCDI standards. (If yes, please complete the table below).

X No, none of my products include these voluntary standards

Standard (and version)	None
Updated certification criteria and associated product	None
Health IT Module CHPL ID	None
Conformance measure	None

Care Setting(s)

Ambulatory → Primary care physicians are the target market for MediFusion, which has been approved for use in ambulatory care settings.

Metrics and Outcomes

Measurement / Metric	Associated Criterion(a)	Relied Upon Software (if applicable)	Outcomes	Challenges Encountered (if applicable)
RWT Measure #1. Number of Transition of Care C-CDAs Successfully Sent Over a 90-day period: 1. Number of standards-conformant C-CDA documents created per month... 2. Number of times per month a C-CDA document was opened and viewed... 3. Number of times per month the C-CDA validator capability was leveraged...	170.315(b)(1) Transitions of care	EMR Direct	**Pass** 1. Monthly Avg: 3,975 2. Monthly Avg: 18,337 3. Monthly Avg: 62,926	N/A
RWT Measure #2. Number of Quality Measures Successfully Reported on to CMS Over a 90-day period: 1. % of selected patients for whom QRDA files are successfully generated (Target=100%) 2. % of patient data successfully imported (Target=90%) 3. % of successful QRDA file submissions	170.315(c)(1-3) Clinical quality measures (CQMs)	N/A	**Pass** 1. 100% (35,000 files / 35,000 eligible patients) 2. 95% (Sample data) 3. 100% (92,569 files / 92,569 attempts)	N/A

RWT Measure #3. Number of Patients Given Access to Portal Over a 90-day period: 1. Number of unique users that viewed health record 2. Total combined viewing events 3. Number of unique users that downloaded/transmitted a CCD 4. Number of unique users that viewed Access Logs 5. Total viewing events of Access Logs	170.315(e)(1) View, download, and transmit to 3rd party	Chrony NTP/3.4	**Pass** 1. 7,441 2. 2,929 3. 542 4. 1,572 5. 5,471	N/A
RWT Measure #4. Number of Electronic Reportable Lab Messages Successfully Sent Over three 10-day periods (within 90 days): 1. % of successful daily reportable lab results transactions (Target=85%+)	170.315(f)(3)	N/A	**Pass - via Interactive Test** 1. 100% (30/30 successful test transactions)	Tested interactively due to no production use. 30 successful HL7 messages were sent to a test public health registry endpoint
RWT Measure #5. Compliance of C-CDA Error Detection Over a 90-day period: 1. % of patient visits with a C-CDA sent/received (Target=50%+) 2. % of inbound C-CDAs with any error (Target<25%) 3. % of customers who changed display settings (Target<5%)	170.315(b)(1)	EMR Direct	**Pass** 1. 78% 2. 12% 3. 2%	N/A

RWT Measure #6. Problem/Medication/Allergy Incorporation from C- CDA – C-CDA Scorecard Quantifiable Result 1. Total Problems added/rejected per month 2. Total Allergies added/rejected per month 3. Total Home Medications added/rejected per month	170.315(b)(2) Clinical information reconciliation and incorporation	N/A	**Pass** 1. Monthly Avg: 1,215 2. Monthly Avg: 1,238 3. Monthly Avg: 1,470	N/A
RWT Measure #7. Immunization Message – Number of Compliant Conformance Statements and Errors Detected Metrics (Interactive Test): 1. Success rate for submissions (VXUs) to valid endpoint (Target=90%) 2. Volume of successful test queries (QBPs) initiated 3. Count of common error types observed (for insight)	170.315(f)(1) Transmission to Immunization registries	N/A	**Pass - via Interactive Test** 1. 100% (45/45 test messages) 2. 15 test queries 3. See note	Tested interactively due to no production use. 45 test VXU messages were successfully submitted to a state IIS test endpoint. Common error simulations (demographics, lot number) were handled correctly by the system.

RWT Measure #8. Syndromic Surveillance Message – Number of Compliant Conformance Statements and Errors Detected Over three 10-day periods: 1. % of successful daily syndromic surveillance transactions (Target=85%+)	170.315(f)(2)	N/A	**Pass - via Interactive Test** 1. 100% (30/30 successful test transactions)	Tested interactively due to no production use. 30 test ADT messages (A01, A03, A04, A08) were successfully sent to a test public health endpoint.
RWT Measure #09. API Resource Query Support – C-CDA Scorecard Quantifiable Result 1. (g10) Single Patient API Success Rate (Target=98%+) 2. (g10) Bulk Data Extraction Count 3. (g9) C-CDA via API Success Rate 4. (g7) Patient Access Token Grant Count	170.315(g)(7), (g)(9), (g)(10)	N/A	**Pass** 1. 99.4% 2. 7 3. 99.8% 4. 19,019	N/A
RWT Measure #10. Direct Project 1. % messages processed in <1 hr (Target=99.9%) 2. Overall system uptime (Target=99.9%)	170.315(h)(1)	EMR Direct	**Pass** 1. 99.94% 2. 99.98%	N/A
RWT Measure #11. Data Segmentation Send 1. Number of protected C-CDAs successfully sent	170.315(b)(7)	N/A	**Pass - via Interactive Test** 1. 25 (test transmissions)	Tested interactively. 25 test documents with segmentation tags were successfully sent via Direct with MDN confirmation
RWT Measure #12. Data Segmentation Receive 1. Number of protected C-CDAs successfully received	170.315(b)(8)	N/A	**Pass - via Interactive Test** 1. 25 (test transmissions)	Tested interactively. 25 test segmented documents were received, parsed, and tagged correctly in the system.

RWT Measure #13. FHIR 1. Success rate of HL7 FHIR API transactions (g10)	170.315(g)(10)	N/A	**Pass** 1. 99.4%	This metric is a focused subset of the data collected for RWT Measure #9, presented for clarity.

0-Outcome Measures and Testing Methodology

RWT Measure #11. Data Segmentation Send (b7)

Outcomes: 0

Testing Methodology:

Interactive test scenario was created to validate the Direct Messaging capability for data segmentation. A sample document was sent using Direct protocol to a test endpoint. Functionality was verified by transmission confirmation and audit logging.

RWT Measure #12. Data Segmentation Receive (b8)

Outcomes: 0

Testing Methodology:

Simulated test using a test message with embedded segmentation tags received at the system endpoint. Parsing and segmentation tagging were validated successfully in the backend logs.

RWT Measure #4. Electronic Reportable Lab Messages (f3)

Outcomes: 0

Testing Methodology:

Due to low use in the production environment, interactive testing was executed. Sample HL7 lab order messages were generated and submitted to confirm the proper structure, validation, and delivery to designated lab endpoints.

RWT Measure #7. Immunization Registry Submission (f1)

Outcomes: 0

Testing Methodology:

Sample immunization messages were sent to a state test registry endpoint using certified HL7 V2 format. Submission was confirmed via transport response and internal logs.

RWT Measure #8. Syndromic Surveillance (f2)

Outcomes: 0

Testing Methodology:

Certified capability was validated by submitting a test syndromic surveillance message via the designated endpoint. No production clients utilized this feature during the testing window.

KEY MILESTONES

Key Milestone	Care Setting	Date/Timeframe
Scheduling and logistics	Ambulatory	7/1/2024-9/25/2024
Data collection	Ambulatory	9/26/2024-12/25/2024
MediFusion executed interactive testing to show that the criterion is functional. The following metrics were tested interactively as detailed in the outcomes section above: • 170.315 (f)(1) Transmission to immunization registries • 170.315 (f)(2) Transmission to public health agencies — syndromic surveillance	Ambulatory	Sep – Dec 2024

Clarification Note:

The separate milestone for f1 and f2 criteria was intentional to allow targeted testing of public health reporting modules. All other criteria were tested within the broader data collection and interactive testing timeframe (Sep–Dec 2024).